GLP-1 Telehealth Red Flags: 10 Warning Signs Before You Hand Over Your Card

The FDA has issued more warning letters to GLP-1 telehealth companies in the past six months than it sent to all pharmaceutical companies in the preceding decade. The NABP has found that roughly half of investigated illegal online pharmacies were selling semaglutide products. And the DOJ is investigating the industry's most prominent player.

Here are the ten warning signs — drawn directly from FDA enforcement patterns and regulatory findings — that a platform isn't worth your money or your trust.

1. "Guaranteed Prescription"

No legitimate telehealth platform can guarantee a prescription. A licensed prescriber must evaluate your individual medical history and make an independent clinical decision. Platforms that guarantee you'll get medication before a provider reviews your case are selling access, not healthcare. The FDA views this language as a misbranding signal.

2. No Named Pharmacy Partner

If a telehealth provider won't tell you which pharmacy compounds and ships your medication, that's one of the clearest red flags in the space. Legitimate platforms work with named, verifiable compounding pharmacies — typically 503A (patient-specific) or 503B (outsourcing facility) registered pharmacies. You should be able to verify the pharmacy independently through NABP or your state board of pharmacy.

3. Marketing That Implies Compounded = FDA-Approved

This is the exact violation at the center of the March 2026 FDA warning letters. If a platform describes its compounded semaglutide or tirzepatide in language that suggests it's the same as Wegovy, Ozempic, Zepbound, or Mounjaro, they're crossing a line the FDA has drawn clearly. Compounded drugs are not generics. They have not undergone FDA review for safety, efficacy, or quality.

4. No Prescriber Credentials Listed

After your consultation, you should be able to identify your prescriber by name and verify their credentials through the NPI Registry and your state medical board. Platforms that keep prescribers anonymous or use vague language like "our medical team" without naming individuals should raise concerns.

5. No Lab Work and No Follow-Up Protocol

While not every legitimate platform requires lab work at intake, every credible one has a protocol for monitoring your response to treatment. If a platform writes a prescription based on a short questionnaire, ships medication, and never contacts you again, that's not medicine — that's a vending machine with extra steps.

6. Hidden Subscription and Auto-Renewal Terms

If you can't find the cancellation policy, refund terms, and full pricing breakdown before entering payment information, look elsewhere. Several platforms have been flagged for subscription traps that charge for months of medication the patient didn't order, with cancellation processes designed to frustrate.

7. "Research Use Only" Products

The FDA issued a warning letter in May 2026 to Gram Peptides for selling substances marketed as "Retatrutide" and "Tirzepatide" labeled for research use — while clearly marketing them for human weight loss. Products labeled "research use only" or "not for human consumption" that are marketed alongside weight loss messaging are unapproved drugs. Period.

8. "Liquid Pearls," "Drops," or Novel Delivery Claims

According to NABP and FDA enforcement guidance, offerings described as "liquid pearls," "drops," or other unconventional forms without clear compounding pharmacy sourcing are a significant red flag. Legitimate compounded GLP-1s come as injectable vials or, in some cases, sublingual formulations from named pharmacies.

9. No HIPAA Compliance Documentation

Telehealth platforms handle sensitive health and payment data. If the privacy policy doesn't explicitly mention HIPAA compliance and you see vague promises or aggressive marketing opt-ins, be cautious about where your health information is going.

10. Price Too Good to Be True — With No Clear Sourcing

Compounded semaglutide genuinely costs less than brand-name Wegovy. But there's a floor. A legitimate 503A or 503B pharmacy has real costs: licensed pharmacists, sterility testing, proper cold-chain shipping. If a platform offers GLP-1 medications at prices far below market ($50/month or less) without naming their pharmacy partner, the sourcing is the question you need to answer before you inject anything.

Providers That Pass the Test